5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy

Experimental Neurology

Volumn 184, Issue 2, 2003, Pages 964-972

  Jakus, Rita ^a   Graf, Marton ^a   Juhasz, Gabriella ^a   Gerber, Katalin ^a   Levay, Gyorgy ^b   Halasz, Peter ^a   Bagdy, Gyorgy ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

5 HT1A receptor; 5 HT2C receptor; Epilepsy; SB 242084; Serotonin; Spike wave discharge; SSRI antidepressant; WAY 100635

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; CITALOPRAM; CITALOPRAM HBR; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1 ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; 1-(3-CHLOROPHENYL)PIPERAZINE; AMINOPYRIDINE DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; EPILEPSY; EXPERIMENTAL MODEL; MALE; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; RAT; SPIKE WAVE; ABSENCE; ACTION POTENTIAL; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ACTION POTENTIALS; AMINOPYRIDINES; ANIMALS; CITALOPRAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EPILEPSY, ABSENCE; FLUOXETINE; INDOLES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; MALE; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0842299485     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00352-2     Document Type: Article

References (49)

1. Bagdy G. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav. Brain Res. 73:1996;277-280.
2. Bagdy G., Makara G.B. Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. Eur. J. Pharmacol. 275:1995;301-305.
3. Bagdy G., Calogero A.E., Murphy D.L., Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology. 125:1989;2664-2669.
4. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 4:2001;399-408.
5. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
6. Baxter G., Kennett G., Blaney F. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol. Sci. 16:1995;105-110.
7. Bonhaus D.W., Bach C., DeSouza A., Salazar F.H., Matsuoka B.D., Zuppan P., Chan H.W., Eglen R.M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 115:1995;622-628.
8. Bonhaus D.W., Weinhardt K.K., Taylor M., DeSouza A., McNeeley P.M., Szczepanski K., Fontana D.J., Trinh J., Rocha C.L., Dawson M.W., Flippin L.A., Eglen R.M. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology. 36:1997;621-629.
9. Brennan T.J., Seeley W.W., Kilgard M., Schreiner C.E., Tecott L.H. Sound-induced seizures in serotonin 5-HT2C receptor mutant mice. Nat. Genet. 16:1997;387-390.
10. Browning R.A., Hoffman W.E., Simonton R.L. Changes in seizure susceptibility after intracerebral treatment with 5,7-dihydroxy-tryptamine: role of serotonergic neurones. Ann. N.Y. Acad. Sci. 305:1978;437-456.
11. Buterbaugh C.G. Effects of drugs modifying central serotonergic function on the response of extensor and non extensor rats to maximal electroshock. Life Sci. 23:1978;2393-2904.
12. Clemett D.A., Punhani T., Duxon M.S., Blackburn T.P., Fone K.C. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology. 39:2000;123-132.
13. Coenen A.M., Drinkenburg W.H., Inoue M., van Luijtelaar E.L. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Res. 12:1992;75-86.
14. Conn P.J., Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C receptors). J. Pharmacol. Exp. Ther. 242:1987;552-557.
15. Daily J.W., Yan Q.S., Mishra P.K., Burger R.L., Jobe P.C. Effects of fluoxetine on convulsions and brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J. Pharmacol. 260:1992;533-540.
16. De La Torre J.C., Kawanaga H.M., Mullan S. Seizure susceptibility after manipulation of brain serotonin. Arch. Int. Pharmacodyn. Ther. 188:1970;298-304.
17. Filakovszky J., Gerber K., Bagdy G. A serotonin-1A receptor agonist and N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci. Lett. 261:1999;89-92.
18. Filakovszky J., Kantor S., Halasz P., Bagdy G. 8-OH-DPAT and MK-801 affect epileptic activity independently of vigilance. Neurochem. Int. 38:2001;551-556.
19. Fone K.C.F., Austin R.H., Topham I.A., Kennett G.A., Punhani T. Effect of chronic m-CPP locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. Br. J. Pharmacol. 123:1998;1707-1715.
20. Gerber K., Filakovszky J., Halasz P., Bagdy G. The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 807:1998;243-245.
21. Graf M., Kantor S., Anheuer Z.E., Modos E.A., Bagdy G. m-CPP-induced self-grooming is mediated by 5-HT2C receptors. Behav. Brain Res. 142(1-2):2003;175-179.
22. Hiramatsu M.K., Kawanaga K., Kabuto H., Mori A. Reduced uptake and release of 5-hydroxytryptamine and taurine in the cerebral cortex of epileptic El mice. Epilepsy Res. 1:1987;40-44.
23. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46:1994;157-203.
24. Jäkälä P., Sirviö J., Koivisto E., Björklund M., Kaukua J., Riekkinen P.J. Modulation of rat neocortical high-voltage spindle activity by 5-HT1/5-HT2 receptor subtype specific drugs. Eur. J. Pharmacol. 282:1995;39-55.
25. Kennett G.A., Wood M.D., Glen A., Grewal S., Forbes I., Gadre A., Blackburn T.P. In vivo properties of SB200646, a 5-HT2C/2B receptor antagonist. Br. J. Pharmacol. 111:1994;797-802.
26. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
27. Kilian M., Frey H.H. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology. 12:1973;681-692.
28. Lopez-Gimenez J.F., Mengod G., Palacios J.M., Vilaro M.T. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse. 42:2001;12-26.
29. Löscher W. Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find Exp. Clin. Pharmacol. 6(9):1984;531-547.
30. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
31. McCormick D.A. Neurotransmitter actions in the thalamus and cerebral cortex. J. Clin. Neurophysiol. 9:1992;212-223.
32. McCormick D.A., Wang Z. Serotonin and noradrenaline excite GABAergic neurones of guinea-pig and cat nucleus reticularis thalami. J. Physiol. 442:1991;235-255.
33. Murphy D.L., Lesch K.P., Aulakh C.S., Pigott T.A. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol. Rev. 43:1991;527-552.
34. Nicoll R.A., Malenka R.C., Kauer J.C. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Psychol. Rev. 70:1990;531-565.
35. Noebles J.L. Targeting epilepsy genes. Neuron. 16:1996;241-244.
36. Pape H.C., McCormick D.A. Noradrenaline and serotonin selectively modulate thalamic burst firing by enhancing a hyperpolarisation-activated cation current. Nature. 340:1989;715-718.
37. Pompeiano M., Palacios J.M., Mengod G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. Mol. Brain Res. 23:1994;163-178.
38. Porter R.H., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., Adams D.R., Sheardown M.J. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol. 128:1999;13-20.
39. Prendiville S., Gale K. Anticonvulsant effect of systemic fluoxetine on focally-evoked limbic motor seizures in rats. Epilepsia. 34:1985;381-384.
40. Przegalinski E. Monoamines and the pathophisiology of seizure disorders. Frey H.H., Janz D. Handbook of Experimental Pharmacology. 1985;101-137 Springer Verlag, Berlin.
41. Przegalinski E., Baran l., Siwanowicz J. Role of 5-hydroxytryptamine receptor subtypes in the 1-[3-(trifluoromethyl)phenyl]-piperazine in mice. Epilepsia. 35:1994;889-894.
42. Statnick M.A., Maring-Smith M.L., Clough R.W., Wang C., Dailey J.W., Jobe P.C., Browning R.A. Effects of 5,7-dihydroxy-tryptamine on audiogenic seizures in genetically epilepsy-prone rats. Life Sci. 59:1996;1763-1771.
43. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 374:1995;542-546.
44. Upton N., Stean T., Middlemiss D., Blackburn T., Kennett G. Studies on the role of 5-HT2C and 5-HT2B receptors in regulating generalised seizure threshold in rodents. Eur. J. Pharmacol. 359:1998;33-40.
45. van Luijtelaar E.L., Drinkenburg W.H., van Rijn C.M., Coenen A.M. Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects? Methods Find. Exp. Clin. Pharmacol. 24(Suppl. D):2002;65-70.
46. Wada Y., Shiraishi J., Nakamura M., Koshino Y. Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res. 747:1997;338-342.
47. Ward R.P., Dorsa D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 370:1996;405-414.
48. Watanabe K., Ashby C.R.J., Katsumori H., Minabe Y. The effect of the acute administration of various selective 5-HT receptor antagonists on focal hippocampal seizures in freely-moving rats. Eur. J. Pharmacol. 398:1999;239-246.
49. Yan Q.S., Jobe P.C., Cheong J.H., Ko K.H., Dailey J.W. Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy prone rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;149-152.